BACH2-modified CD22-targeting CAR T cells

BACH2-modified CD22-targeting CAR T cells are an experimental autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to recognize the B-cell surface antigen CD22 while incorporating genetic modulation of the transcription factor BACH2 to improve T-cell fitness, persistence, and antitumor potency. Like other CD22-directed CAR-T products, these cells express a synthetic receptor comprising an anti-CD22 single-chain variable fragment fused to T-cell signaling and costimulatory domains, enabling targeted killing of CD22-positive B-cell malignancies such as B-cell acute lymphoblastic leukemia that relapse or are refractory after CD19-directed therapies.[1][2] The additional BACH2 modification is intended to reprogram T-cell differentiation and exhaustion pathways, potentially sustaining CAR-T expansion and durability in the face of low or dynamically downregulated CD22 antigen density, a known resistance mechanism to CD22-targeted CAR-T therapy.[2][11]